Literature DB >> 16772766

Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent.

Ricardo P Garay1, Carlo Chiavaroli, Patrick Hannaert.   

Abstract

Ethamsylate (2,5-dihydroxy-benzene-sulfonate diethylammonium salt) is a synthetic hemostatic drug indicated in cases of capillary bleeding. This review covers more than 40 years of intensive clinical and fundamental research with ethamsylate. First, we summarize the large medical literature concerning its clinical efficacy. Of these, well-controlled clinical trials clearly showed the therapeutic efficacy of ethamsylate in dysfunctional uterine bleeding, with the magnitude of blood-loss reduction being directly proportional to the severity of the menorrhagia. Other well-controlled clinical trials showed therapeutic efficacy of ethamsylate in periventricular hemorrhage in very low birth weight babies and surgical or postsurgical capillary bleeding. Second, we review the numerous investigations performed to elucidate the mechanism of action of ethamsylate. Ethamsylate acts on the first step of hemostasis by improving platelet adhesiveness and restoring capillary resistance. Recent studies showed that ethamsylate promotes P-selectin-dependent, platelet adhesive mechanisms. Finally, we compare ethamsylate with other recent hemostatic agents. It is suggested that the place of ethamsylate as a hemostatic agent is that of a mild but well-tolerated drug, particularly useful in dysfunctional uterine bleeding when contraception is not needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772766     DOI: 10.1097/01.mjt.0000158336.62740.54

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  10 in total

Review 1.  Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts.

Authors:  Shenandoah Robinson
Journal:  J Neurosurg Pediatr       Date:  2012-03       Impact factor: 2.375

Review 2.  Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.

Authors:  Sujoy Ray; Amita Ray
Journal:  Cochrane Database Syst Rev       Date:  2016-11-10

3.  Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions.

Authors:  Selene Imbesi; Eustachio Nettis; Paola L Minciullo; Elisabetta Di Leo; Antonella Saija; Angelo Vacca; Sebastiano Gangemi
Journal:  Pharm World Sci       Date:  2010-07-15

Review 4.  Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis.

Authors:  Magdalena Bofill Rodriguez; Sofia Dias; Vanessa Jordan; Anne Lethaby; Sarah F Lensen; Michelle R Wise; Jack Wilkinson; Julie Brown; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2022-05-31

Review 5.  A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 6.  A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles.

Authors:  Soha M El-Masry; Sally A Helmy
Journal:  Saudi Pharm J       Date:  2020-11-06       Impact factor: 4.330

8.  Beneficial effects of early hemostasis on spinal cord injury in the rat.

Authors:  H Fan; K Chen; L Duan; Y-Z Wang; G Ju
Journal:  Spinal Cord       Date:  2016-05-03       Impact factor: 2.772

Review 9.  Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.

Authors:  Jenna E Koschnitzky; Richard F Keep; David D Limbrick; James P McAllister; Jill A Morris; Jennifer Strahle; Yun C Yung
Journal:  Fluids Barriers CNS       Date:  2018-03-27

10.  Hemostatic Agents in Critically Ill Patients.

Authors:  Saurabh Kumar Das; Maheeja Maddi Reddy; Sumit Ray
Journal:  Indian J Crit Care Med       Date:  2019-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.